

Injection Devices for Biological Drugs

Technologies, Therapeutics,
Markets, Strategies &
Forecasts

Report Brochure




Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Injection Devices for Biological Drugs: Devices, Therapeutics, Markets, Strategies and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injection devices for administering biologicals. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Device Engineering Becoming the Linchpin to Continued Biological Drug Growth

Biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.



Executive Summary

The Market Opportunity

Unmet Patient Needs

Biosimilars

The Biological Drug Global Supply Chain

Biological Drug Delivery – Challenges and Limitations

Drug Stability

Pre- and Post-Manufacturing Engineering

Lyophilization and Reconstitution

Viscosities and Volumes

Drug Strategies & Therapeutic Protein Packaging

As-Supplied Packaging

Device Market Share

Device Supplier Segment Activity

Emerging Injection Devices for Biological Drugs

Injectable Biologicals - Product Analysis by Drug Class

Cytokines

Enzymes

Fusion Proteins

G-CSF/GM-CSF

Hematopoietics

Hormones

Immune Modulators

Insulins & GLP Analogs

Monoclonal Antibodies

Vaccines

Therapeutic Market Segment Analysis

Cardiovascular

Diabetes

Hematology

Immunology

Metabolic

Oncology

Market Factors

Regulatory Issues

Patient Preferences and Self-Administration

Pre- and Post-marketing Device Evolution

Compatibility Testing

Company Profiles

What You Will Learn

- What are the product and user requirements that drive the biological drug-device selection process?
- What are the essential design factors, technologies and market development issues for injection devices capable of administering biological drugs?
- What is the impact of development-stage biological manufacturing process changes on device go-to-market readiness and how has it changed in recent years?
- How do device selection decisions align across biological drug classes? Therapeutic targets? Market segments?
- What is the impact of drug-device dependencies on pre- and post-marketing product life cycle management?
- What are the significant economic, technology, and regulatory factors affecting the market for biological drug injection devices?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Injection Devices for Biological Drugs

Technologies, Therapeutics, Markets, Strategies and Forecasts

| Select | Format | License | Price (U.S. Funds) | Total |
|-----------------------------------|--------|---------------------|--------------------|-------|
| <input type="checkbox"/> | PDF | Single User License | \$3,850.00 | |
| <input type="checkbox"/> | PDF | Site License | \$5,500.00 | |
| <input type="checkbox"/> | PDF | Global License | \$8,500.00 | |
| Total Payment (U.S. funds) | | | | |

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

| Billing Information | Shipping Information |
|----------------------|---|
| Name: | <input type="checkbox"/> Click here if same as Billing Information Name: |
| Title: | Title: |
| Company: | Company: |
| Street Address: | Street Address: |
| City,State/Province: | City,State/Province: |
| Country/Postal Code: | Country/Postal Code: |
| Phone: | Phone: |
| Fax: | Fax: |
| Email: | Email: |